Characteristics Associated with Bone Mineral Density Responses to Alendronate in Men
| Autor: | Erik Dean Swenson, Karen E. Hansen, Brooke Baltz-Ward, Arthur A. Schuna, Mary E. Elliott, Zhanhai Li, Andrea N. Jones |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
musculoskeletal diseases medicine.medical_specialty Bone density Endocrinology Diabetes and Metabolism Osteoporosis Lumbar vertebrae Article Absorptiometry Photon Endocrinology Bone Density Internal medicine medicine Humans Orthopedics and Sports Medicine Aged Retrospective Studies Bone mineral Hip Lumbar Vertebrae Alendronate Bone Density Conservation Agents business.industry Body Weight Weight change Age Factors musculoskeletal system medicine.disease medicine.anatomical_structure Concomitant Physical therapy medicine.symptom Multivitamin business Weight gain |
| Zdroj: | Calcified Tissue International. 92:548-556 |
| ISSN: | 1432-0827 0171-967X |
| DOI: | 10.1007/s00223-013-9715-9 |
| Popis: | Some patients experience reduced bone mineral density (BMD) despite bisphosphonate therapy. We performed a retrospective chart review study to detect factors associated with decreased BMD in men prescribed alendronate. Two investigators reviewed eligible medical records and used a standardized form to record potential characteristics predicting men's response to alendronate. We analyzed patient characteristics associated with annualized change in hip and spine BMD (D-BMD). Among 115 eligible men, 19 (17 %) experienced significantly decreased BMD at the hip or spine, defined as a change exceeding precision error. Eleven men (10 %) fractured during therapy. Spine D-BMD was positively associated with adherence to alendronate (R = 0.23, p = 0.02) and inversely associated with baseline body weight (R = -0.21, p = 0.03). Hip D-BMD was positively associated with annualized weight change (R = 0.19, p = 0.0498) and negatively associated with patient age and number of concomitant medications (R = -0.21, p = 0.03; R = -0.20, p = 0.03, respectively). In stepwise linear models, spine D-BMD was associated positively with alendronate adherence and multivitamin use and negatively with baseline body weight. Hip D-BMD was negatively associated with age. Fracture during treatment was associated with fracture prior to therapy (p = 0.03). In this small study of men prescribed alendronate, BMD response showed a positive association with adherence to therapy, weight gain, and use of a multivitamin. By contrast, older age, higher baseline body weight, and higher number of medications were each associated with a decrease in BMD. Larger studies are needed to confirm and extend these findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink